[Edaily Reporter Hyera Lee ] #DongBang Medical Co., Ltd. announced on the 3rd that it recently participated in “The Aesthetic Show 2026,” an aesthetic medicine conference held in Las Vegas, USA, and introduced its own brand, Miracu. The medical thread “Miracu.” (Photo courtesy of DongBang Medical Co., Ltd.) Miracu is a cannula-integrated polydioxanone (PDO) thread product that encompasses a diverse lineup of threads—including Mono, Screw, and Cog—as well as dedicated cannulas. It is the first brand in the soft tissue adhesion product category to receive U.S. Food and Drug Administration (FDA) 510(k) Class II clearance. DongBang Medical Co., Ltd., the world’s largest manufacturer of cannulas and PDO threads, showcased its Miracu cannula and PDO thread product line at the event under the slogan “See Everything. Miss Nothing,” emphasizing precise visibility and safety. In particular, the company unveiled new needles and syringes designed specifically for skin boosters for the first time at this event. The specialized needle design, which aids in precise procedures, and the syringe’s ease of use drew significant interest from medical professionals in attendance. DongBang Medical Co., Ltd. conducted live demonstrations of Miracu products and provided training on procedural techniques for conference participants. A DongBang Medical Co., Ltd. representative stated, “Through this participation, we aimed to convey both the reliability of our FDA-approved, clinically validated products and our expertise in precise procedures to medical professionals in the U.S. market.”
SamsungElectronics is expected to become the first South Korean company to enter the era of quarterly operating profit exceeding 100 trillion won. Buoyed by a boom in the memory semiconductor market d…
The convenience store industry is expanding its network of specialty stores that focus on specific product categories for each company. With the number of convenience stores in South Korea exceeding 5…
(Graphic: ChatGPT)
Three deals involving Korean companies were included among the top 10 influential transactions in the Asia-Pacific pharmaceutical and biotech market this year. SAMSUNG BIOLOGICS…